Brands
Gulf Oil inks partnership pact with Manchester United
MUMBAI: Gulf Oil Lubricants India Ltd (GOLIL) announced that its parent company Gulf Oil International, a part of the Hinduja Group, had entered into its largest ever single partnership with Manchester United to become its global sponsor and official lubricant cum fuel retail partner till end of 2019 football season.
Spanning over three seasons, this multi-year partnership was signed by Gulf Oil International vice president Frank Rutten and Manchester United commercial director Jamie Reigle. “We were working on this deal for over a year and a half. International football is the biggest platform in the world, and Manchester United a celebrated brand, we couldn’t find a more fitting partner for association given our ambitious target across the world for 2020,” said Gulf Oil International vice president Frank Rutten.
The deal will give Gulf Oil International access to Manchester United assets including the club crest and player images and Gulf’s distinctive orange disc will feature on the Club’s digital perimeter boards during Premier League, FA Cup and League Cup matches at Old Trafford though it does not include jersey presence for the brand.
The company’s partnership with Manchester United is in addition to its existing global tie-ups with Milwaukee BMW, World Superbikes, the World Endurance Championship with the Gulf Racing Team and Porsche.
Commenting on this partnership’s mileage in the Indian market, GOLIL managing director Ravi Chawla added, “Gulf Oil’s association with the world of sports has been phenomenal right from motorsports to cricket, where we have partnered with the best of the best. It was therefore logical for us to team up with Manchester United in order to reiterate our brand’s core values of endurance, quality and passion. We look forward to leverage this interesting mix of football and cricket and leverage this partnership to increase consumer engagement with the brand, create new and exciting communication platforms that will emphasis the customer value propositions.”
The company expects the tie-up with Manchester United to augment its long-term association with cricket for enhancement and further strengthening of its brand equity amongst its customers, especially for personal mobility consumers who use two wheelers or passenger cars.
After cricket, football is the second most popular sport in India. In recent years with the emergence of domestic leagues, the popularity of the sport is growing exponentially to reach youth, not just in the metros but in the tier-1 and tier-2 cities as well. Moreover, viewership of English Premier League & other football tournaments is gaining momentum in India.
The partnership marks a further step in Gulf’s intent to strengthen its brand presence globally as well as enable it to engage with Manchester United’s worldwide fan base, including 325 million followers in Asia, which Gulf sees as a major focus area with a strong presence in India and rapidly developing businesses in China, the Middle East and Indonesia.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
